Evidence map›Paper›PMID 24281237›Full record

Trial reportMenopause (New York, N.Y.)2014

Testosterone dose-response relationships in hysterectomized women with or without oophorectomy: effects on sexual function, body composition, muscle performance and physical function in a randomized trial.

Grace Huang, Shehzad Basaria, Thomas G Travison, Matthew H Ho, Maithili Davda, Norman A Mazer, Renee Miciek, Philip E Knapp, Anqi Zhang, Lauren Collins and 12 more

2 registry-linked trialsOpen access · greenAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Menopause (New York, N.Y.), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 45 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed, 2 pooled it
3.4field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03210558 phase2completednot on this mapstarted 2017, after this paper: background citation

Effects of Moderately Increased Testosterone Concentration on Physical Performance and Behaviour in Healthy Women - a Double-blind, Randomized, Placebo-controlled Study

TypeinterventionalSponsorKarolinska University HospitalRan2017 to 2018Enrolled48ConditionsAthletic Performance, Testosterone, Women's Health: Female Athlete/Female Athlete TriadArmsTestosterone cream 1% (Andro-Feme® ), Placebo cream
NCT04026880 phase3withdrawnnot on this mapstarted 2021, after this paper: background citation

A Pilot Study To Evaluate The Effect of Testosterone Enanthate On Structural and Functional Characteristics of Pelvic Floor Muscles In Postmenopausal Women With Urinary Incontinence

TypeinterventionalSponsorBrigham and Women's HospitalRan2021 to 2022Enrolled0ConditionsUrinary Incontinence, MenopauseArmsTestosterone Enanthate, Placebo
3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 2 syntheses or guidelines pooled it, 114 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Review
  11. Metabolic Messengers: testosterone.Nature metabolism · 2026
    Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Review
  19. Evaluation of Sexual Function of Transgender Individuals.International urogynecology journal · 2024
    Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 3 institutions in 1 country.

Grace HuangFrom the 1Section of Endocrinology, Diabetes, and Nutrition, Boston University School of Medicine and Boston Medical Center, Boston, MA; 2Department of Biostatistics, Boston University School of Public Health, Boston, MA; 3Division of Endocrinology, Metabolism, and Molecular Medicine, Charles R. Drew University of Medicine and Science, Los Angeles, CA; and 4Division of Female Pelvic Medicine and Reconstructive Surgery, Department of Obstetrics and Gynecology, Harbor-UCLA Medical Center, University of California, Los Angeles, CA.
Shehzad Basaria
Thomas G Travison
Matthew H Ho
Maithili Davda
Norman A Mazer
Renee Miciek
Philip E Knapp
Anqi Zhang
Lauren Collins
Monica Ursino
Erica Appleman
Connie Dzekov
Helene Stroh
Miranda Ouellette
Tyler Rundell
Merilyn Baby
Narender N Bhatia
Omid Khorram
Theodore Friedman
Thomas W Storer
Shalender Bhasin
Boston Medical Center · USBoston University · USCharles R. Drew University of Medicine and Science · US

Funding

TUFTS--FIELDINGP30AG031679 · NIA · BRIGHAM AND WOMEN'S HOSPITAL · PI Ravi Jasuja · 2008 to 2026
$23.9M
THE BIOLOGIC EFFECTS OF ANDROGENS IN MEN AND WOMENU54HD041748 · NICHD · CHARLES R. DREW UNIVERSITY OF MED &SCI · PI FRIEDMAN, THEODORE C · 2003 to 2010
$6.5M
NIA NIH HHS 5P30AG031679NIA NIH HHS P30 AG031679NICHD NIH HHS 5U54HD041748-04NICHD NIH HHS U54 HD041748
6 · The paper itself

Abstract

objectiveThis study aims to determine the dose-dependent effects of testosterone on sexual function, body composition, muscle performance, and physical function in hysterectomized women with or without oophorectomy.

methodsSeventy-one postmenopausal women who previously underwent hysterectomy with or without oophorectomy and had total testosterone levels less than 31 ng/dL or free testosterone levels less than 3.5 pg/mL received a standardized transdermal estradiol regimen during the 12-week run-in period and were randomized to receive weekly intramuscular injections of placebo or 3, 6.25, 12.5, or 25 mg of testosterone enanthate for 24 weeks. Total and free testosterone levels were measured by liquid chromatography-tandem mass spectrometry and equilibrium dialysis, respectively. The primary outcome was change in sexual function measured by the Brief Index of Sexual Functioning for Women. Secondary outcomes included changes in sexual activity, sexual distress, Derogatis Interview for Sexual Functioning, lean body mass, fat mass, muscle strength and power, and physical function.

resultsSeventy-one women were randomized; five groups were similar at baseline. Sixty-two women with analyzable data for the primary outcome were included in the final analysis. The mean on-treatment total testosterone concentrations were 19, 78, 102, 128, and 210 ng/dL in the placebo, 3-mg, 6.25-mg, 12.5-mg, and 25-mg groups, respectively. Changes in composite Brief Index of Sexual Functioning for Women scores, thoughts/desire, arousal, frequency of sexual activity, lean body mass, chest-press power, and loaded stair-climb power were significantly related to increases in free testosterone concentrations; compared with placebo, changes were significantly greater in women assigned to the 25-mg group, but not in women in the lower-dose groups. Sexual activity increased by 2.7 encounters per week in the 25-mg group. The frequency of androgenic adverse events was low.

conclusionsTestosterone administration in hysterectomized women with or without oophorectomy for 24 weeks was associated with dose and concentration-dependent gains in several domains of sexual function, lean body mass, chest-press power, and loaded stair-climb power. Long-term trials are needed to weigh improvements in these outcomes against potential long-term adverse effects.

Indexed as

HysterectomyAndrogensArousalBody CompositionDose-Response Relationship, DrugFemaleHumansMiddle AgedMuscle, SkeletalMuscle StrengthOvariectomyPostmenopauseSexual BehaviorSexualityTestosteroneAndrogensTestosteronetestosterone enanthate

Identifiers

PMID24281237
PMCPMC4701202
OpenAlexW2079399680

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.